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NOTE
JUST SAY NO: THE CIPRO CRAZE AND

MANAGED CARE-APPLYING THE HAND
FORMULA TO MANAGED CARE DECISIONS
I.

INTRODUCTION

September 11, 2001, marked a new era in world history and in the
way freedom is defined in the United States.' It was a day that saw
hijacked commercial jetliners strike each of the Twin Towers and the
Pentagon. 2 It was a day that saw the Twin Towers, symbolic monuments
of American economic prosperity, crumble to the ground! It was a day
in which the terrorist network led by radical militant Osama bin Laden
effectively declared war on the free world, specifically the United States
and its allies.4

I. See N.R. Kleinfield, A Creeping Horror: Buildings Bum and Fall as Onlookers Search
for Elusive Safety, N.Y. TIMES, Sept. 12, 2001, at Al (describing the day of terror that engulfed
New York, Washington, and the world as a coordinated terrorist attack was carried out in the United
States). After the first plane hit One World Trade Center, many government officials first believed
that this was merely an accident of a commercial airliner gone astray. See Glen Johnson, US Troops
are Put on Highest Alert, BOSTON GLOBE, Sept. 12, 2001, at A10. When the second of the Twin
Towers was struck eighteen minutes later, it was apparent that this was an act of terrorism. See id.
2. See Kleinfield, supranote I.
3. See id.
4. See Alison Mitchell & Philip Shenon, Agreement on $40 Million for Aid and a Response,
N.Y. TmES, Sept. 14, 2001, at A19. While the United States was eager to punish those responsible
for the attacks, the identity of the culprit was uncertain in the early aftermath. See id. Senator John
B. Breaux acknowledged .'[there was almost unanimity that we want to go after whoever was
responsible."' Id. The problem faced was that "you can't just go off and declare war when you don't
know who you are declaring war against." Id. Within weeks, American officials came public and
stated that thare is credible evidence to believe that Osama bin Laden's al Qaeda network
coordinated the attack. See Vernon Loeb & Charles Lane, U.S. Unsure on Going Public With ProofProtecting Intelligence Sources, Methods at Issue in Case Against Bin Laden, WASH. POST, Sept.
25, 2001, at A12. In the months directly following the attacks, a series of government releases made
public evidence directly linking bin Laden to the attacks, culminating in a video release in which bin
Laden spoke of having knowledge of the attacks prior to September 11, 2001. See James Risen, A
Gaunt bin Laden on New Tape, N.Y. TIMES, Dec. 27, 2001, at Al.
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On October 7, 2001, the United States struck back, officially acting
upon its declaration of war on terrorism.5 While explosions could be
heard in the Afghan cities of Kabul, Islamabad, and Kandahar,6 the
United States was on edge after the Federal Bureau of Investigation
("FBI") issued alerts that new terror attacks could loom ahead.7 The
possibility that these new attacks could take the face of bioterrorism
surfaced as rare cases of inhalation anthrax were reported in Florida!
While the FBI is leaning towards the possibility that these new attacks
were carried out by an American loner with an agenda, it is not denied
that the terrorist attacks of September 11, 2001, have left the nation
vulnerable enough to allow for the biological attacks.9 Within three
weeks of the first signs of anthrax' infection surfacing in early October
5. See David Rhode, Thunderous Blasts and Bright Flashes Mark Kabul Strikes, N.Y.
TIMEs, Oct. 8, 2001, at Al; see also Daniel J. Wakin & Charlie LeDuff, Among New York Muslints,
Support for U.S. Strikes, N.Y. TIMES, Oct. 8, 2001, at BI (describing the sentiment among
American Muslims in regards to the "long-awaited United States retaliation for the Sept. 11 terrorist
attacks").
6. See Edward Cody, Taliban Claims Large Civilian Casualties: Afghan Rulers Increase
Efforts to Win Support From Islamic World, WASH. POST, Oct. 12, 2001, at A23. The United States
did not limit its attacks to Osama bin Laden and his al Qaeda network, but also targeted the ruling
Taliban government of Afghanistan. See id. (describing that the attacks were also directed at
Taliban strongholds within Afghanistan). Afghanistan, which has housed Osama bin Laden since
his exile from Saudi Arabia, was the target of attacks because they are a nation "that 'feed (and)
house' terrorists." Paul West, PresidentFinds Unity in Shift of Priorities:Bush Vows to End Threat
of Terrorism:Long Struggle Looms: Terrorism Strikes America, BALT. SUN, Sept. 16, 2001, at IA;
see also Robert D. McFadden, Bin Laden's Journeyfrom Rich, PiousBoy to the Mask of Evil, N.Y.
TIMES, Sept. 30, 2001, at B5 (describing the path of Osama bin Laden from Saudi exile to terrorist
leader).
7. See Anthony DePalma, Fearand Vigilance as Security Plans are Reviewed, N.Y. TIMES.
Sept. 22, 2001, at B6.
8. See John-Thor Dahlburg, U.S Strikes Back: The Biological Threat: 2nd Man Exposed to
Anthrax, L.A. TIMES, Oct. 9, 2001, at Al (quoting Attorney General John Ashcroft as stating "'we
don't have enough information to know whether this could be related to terrorism or not."').
Although "[slome members of Congress are convinced" that the anthrax attacks are attributable to
"Middle Eastern terrorists, intent on following up on the horror of [September] 11," many others
believe that the wave of anthrax poisonings are the doings of "homegrown hate groups" preying on
the vulnerability of the nation after September 11, 2001. See, e.g.,Nicole Sterghos Brochu, Anthrax
Suspects? Your Guess is as Good as FBI's, SUN-SENTINEL (Fort Lauderdale, FL), Nov. 15, 2001. at
23A.
9. See Brochu, supra note 8.
10. Anthrax, biologically known as bacillus anthracis. is a spore-forming bacteria. See
Frequently
Asked
Questions
About
Anthrax,
at
http:llwww.bt.cdc.gov/DocumentsApp/faqanthrax.asp (last visited Mar. 26, 2002). When humans
inhale these spores, they settle in the lungs and cause respiratory failure and death. See Amot Ogden
Medical Center, Communicable Diseases, at http://www.aomc.orglComDiseases/Anthrax.html (last
visited Mar. 26, 2002). Humans can become infected by anthrax in one of three ways: cutaneous.
inhalation, and gastrointestinal. See Frequently Asked Questions About Anthrax, supra. "If left
untreated, anthrax in all forms can lead to ... death." Id. The fatality rates associated with anthrax
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2001 in two employees of Florida-based media firm, American Media,
traces of the bacteria surfaced at the office of then-Senate majority
leader Tom Daschle, mail rooms of various media outlets in New York,
and postal facilities in Washington, Florida, New York and New
Jersey." The unprecedented outbreak of anthrax created a spike in the
demand for the antibiotic Cipro.12 Cipro, a quinolone-base antibiotic
developed and patented by Bayer pharmaceuticals is the most highly
recognized treatment for and prophylactic agent against anthrax
infection. 3
This war, initiated by the deadly attacks of September 11, 2001, has
raised the question of whether Managed Care Organizations ("MCOs"),
which provide medical insurance coverage, should pay for doses of
Cipro used for prophylactic purposes when the intended recipient of the
infection vary depending on which form of the bacteria the infected person contracts. See id. Early
treatment is important for recovery in all forms. See id. Patients with the skin form of anthrax will
die twenty percent of the time without antibiotic treatment, but with treatment, the fatality rate drops
to less than one percent. See id. Patients untreated with the gastrointestinal form of anthrax have a
fatality rate of twenty-five to sixty percent. See id. There is insufficient data to calculate a fatality
rate for gastrointestinal anthrax with early antibiotic treatment but based on the success rate
associated with the skin form of anthrax, we could assume that the fatality rate would drop
significantly. See id. The most troublesome form of the disease is inhalation anthrax. See id. Early
data compiled by the Centers for Disease Control ("CDC") are insufficient to calculate a fatality rate
for this rare form of the disease, but it is postulated that the rate is extremely high even with
antibiotic treatment. See id. As of November 1, 2001, of the ten cases of inhalation anthrax within
the United States, there have been four deaths. See CDC Cotfirned Cases of Anthrax,
http://www.bt.cdc.gov/DocumentsApp/Anthrax/ 1.012001/11012001noon.asp (last visited Mar. 26,
2002). While this small sample may not be enough to contradict past data, the current forty percent
fatality rate is more promising than early medical literature that suggests a ninety percent fatality
rate. See Center for Civilian Biodefense Strategies, Anthrax Fact Sheet 1999, at
http:llwww.hopkins-biodefense.orglpageslagentslagentanthrax.html (last visited Mar. 26, 2002).
11. See Dahlburg, supra note 8; David Firestone, The FirstAnthrax Case: Spores Found at
Post Office in Boca Raton, N.Y. TIMES, Oct. 16, 2001, at B7; Steven Greenhouse, Union Wants
Postal Center Fully Cleaned, N.Y. TIMES, Oct. 27, 2001, at B6 (reporting that anthrax spores have
been found at postal facilities in New York, New Jersey, and Washington); David Johnston &
Alison Mitchell, Airborne Threat: U.S. Says it Could Have Been Made By Expert, Adding to
Concern, N.Y. TIMES, Oct. 17, 2001, at Al (describing cases of Anthrax found at media giants NBC
and ABC); John Schwartz, Efforts to Cahn the Nation's FearsSpin Out of Control, N.Y. TIMES,
Oct. 28, 2001, sec. 4, at 1 (describing the composition of the anthrax delivered to the office of
Senator Tom Daschle).
12. See Tamar Lewin, Bioterrorisin and Anxiet, are Swelling Prescriptions, N.Y. TIMES,
Nov. 1, 2001, at B10 (reporting that following the first reported case of anthrax in Boca Raton,
Florida, prescriptions for the antibiotic Cipro were up sixteen percent nationwide and seventy-three
percent in New York). Interestingly, prescriptions for antidepressants increased by five percent in
early October 2001. See id.
13. See Sheryl Gay Stolberg, U.S. Switches to OlderDrug Against Anthrax, N.Y. TIMES, Oct.
30, 2001, at BS. The cost of Cipro and the problems of stockpiling large quantities of the drug have
led federal health authorities to begin administering an older, but effective antibiotic, Doxycycline.
See id.
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antibiotic is yet to be exposed to anthrax. While the question may be
new with regard to Cipro
treatment, the question of "preventative
4
medicine" certainly is not.'
Further, another battle continues within the walls of Congressspecifically over the Patients' Bill of Rights, which would allow health
insurance consumers to sidestep the Employee Retirement Income
Security Act of 1974 ("ERISA") thereby allowing them to sue their
MCOs for malpractice. 5 This battle rages on as the House of
Representatives and the Senate continue to agree to disagree on the
extent that patients will be protected from their MCOs. 6 The ultimate
passage 7 of the Patients' Bill of Rights will open the door for
unprecedented litigation and leave the judiciary asking how an MCO's
decision regarding patients' treatment is to be scrutinized and exactly
what health insurance malpractice is.
Part II of this Note discusses the Managed Care model, and how it
came to change the American health care system. Part Ill argues that
most medicine is preventative and that there is little distinction between
preventative and curative medicine, contrary to what MCOs would like
us to believe. Part IV recommends a reasonableness standard be used
when judging MCO treatment decisions. Part V discusses ERISA and
how it came to bar plaintiffs from suing their MCOs. Part VI discusses
the Patients' Bill of Rights and the steps that some individual states have
taken to protect their citizens. Part VII applies the reasonableness
standard to the prophylactic use of Cipro and concludes that such use
should not be insured by MCOs unless the patient has actually been
exposed to anthrax. Part VIII discusses the role that the Provider plays in
the Managed Care modality.

14. See Peter McKenna, Managed Care: Failed Experiment or Needed Cost-Cutter?.
INVESTOR'S Bus. DAILY, Sept. 24, 1999, at B2 (describing the managed care system and whether or
not the philosophy of preventative medicine actually decreases costs).
15. See Timothy Hoff, Health Care For All: It's Time For the Insured Majorit' to Take
Notice of the Millions Still Without Health Coverage, TIMES UNION (Albany, N.Y.), Dec. 9, 2001, at
B1.
16. See id. Members of both the House of Representatives and the Senate are eager to pass a
Patients' Bill of Rights, but have been unable to agree on the details. See e.g., 146 CONG. REC. H
12012 (daily ed. Dec. 5, 2000) (statements of Speaker pro tempore Mr. LaTourette). President
George W. Bush, who during his tenure as Governor of Texas "enacted one of the most
comprehensive patient protection laws in the Nation," strives for a similar result. Id.
17. This Note assumes that the Patients' Bill of Rights will ultimately be passed through
Congress.
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1333

THE RISE OF MANAGED CARE

The dynamics of health insurance have transformed since the 1930s
when only one out of thirty-five employees was insured for non-work
related illnesses."t At that time, ninety-seven percent of the work force
was medically uninsured. 9 Traditionally, the individual paid a fee-forservice to the medical professional that rendered the care for that
individual.20 There was no insurer to act as a middleman between the
medical provider and the patient.2 ' The birth of Blue Cross hospital
insurance in the 1930s was the beginning of a popular trend towards
insuring health care.2 In 1939, the Michigan State Medical Society
initiated a plan to insure the costs of surgeons and other specialist care
offered in hospitals.2 This marked the beginning of the Blue Shield plan
that enrolled fifteen million members by 1950 and fifty-six million by
1962.24 Although the early insurance plans limited coverage to
employees, by the late 1940s, sole proprietors and those employees who
were not offered insurance coverage through their employers, were
given the option of purchasing individual policies.2 Within forty years
of the original Blue Cross hospital plan, some sort of insurance policy
covered seventy-four percent of individuals. 6 A quick glance at the
statistics may suggest that the problem of health insurance was solved,
but a deeper look tells an opposite tale; those with health insurance
found that their plans had numerous limitations and restrictions and a

18. See CHARLES ANDREWS, PROFIT FEVER: THE DRIVE TO CORPORATIZE HEALTH CARE
AND HOW TO STOP IT 3 (1995) (citing a 1930 study which "found that only one million of 35
million workers had any [medical] coverage for nonoccupational ailments").
19. See id. Recognizing this problem, on January 1, 1930, Baylor University Hospital offered
public school teachers limited coverage, where in exchange for six dollars per year they would be
entitled to three weeks of physician ordered hospitalization. See id. The plan was created after the
hospital found that many of its outstanding bills were from delinquent teachers. See id. The plan
was extremely popular, and by the year 1935, there were 23,000 enrollees. See id. Within two years
of the initiation of the Baylor University Hospital plan, seven other nonprofit hospitals in
Sacramento, California created comparable plans. See id. There was however a difference that made
the new plans resemble the managed care system as we know it today; the California hospitals
created a separate "nonprofit health insurance company to administer their plan." Id.
20. See id. at 4.
21. Seeid. at3.
22. See id. at 4.
23. See id. at 5.
24. See id.
25. See id. at 6 (discussing that with the commercialization of insurance, companies sold forty
million individual policies).
26. See id. at 7. By 1961, there were eight hundred commercial insurance companies marked
by restrictions and limitations that were uncharacteristic of the original Blue Cross plans. See id.
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majority of the elderly, who represent a majority of the billions of
dollars spent on health care, were uninsured.27 In addition, advancements
in medical technology added a new problem to the mix: rising costs.:8
There have been numerous culprits named for the rapid, extensive
rise in the cost of health care. Already mentioned is the unusual
' A
phenomenon referred to as the "paradox of medical technology."29
second factor leading to increased costs of care was the fee-for-service
model of health care. 30 Along those lines, the fee-for-service model also
encouraged physicians to practice defensive medicine." Defensive
medicine is the practice by which "the impetus for ordering additional
tests and procedures is net primarily to benefit the patient but, rather, to
reduce the prescribing physician's exposure to malpractice liability
risk."32 The practice of defensive medicine by a physician does not take
into account the externalities of rising health care costs1 Defensive
medicine found physicians selfishly overtreating patients in order to
27. See id. at 7. While the problem of the uninsured may seem to have been solved, the
statistics were very deceiving. The exclusions and limitations of these insurance plans left many
medical bills unpaid and the beneficiaries of the plans wondering where their insurance went. See
id. To make matters worse, sixty-six percent of senior citizens aged sixty-five and over were
uninsured. See id. A discussion of Medicare, the solution for the elderly, would encompass an entire
scholarly article and is beyond the scope of this Note.
28. See ARNOLD BIRENBAUM, MANAGED CARE: MADE IN AMERICA 1-2 (1997); Jose L.
Gonzalez, A Managed Care Organization'sMedical Malpractice LiabilitY for Denial of Care: The
Lost World, 35 Hous. L. REv. 715, 722 (1998) (discussing the rising costs of health care); Michael
J. Malinowski, Capitation, Advances in Medical Technology, and the Advent of a New Era in
Medical Ethics, 22 AM. J.L. & MED. 331, 341 (1996) (discussing the "paradox of medical
technology" in that as technology advances and improves medicine, the greater the cost of heal h
care becomes). The rising cost of medicine associated with technological advancement is contrary
to other industries where new technology increases efficiency and decreases costs. See Larry E.
Ribstein, Limited Liability Unlimited, 24 DEL. J. CORP. L. 407, 416 (1999) (discussing the
decreasing costs and prices associated with technological development).
29. See Malinowski, supra note 28, at 341, see also Gonzalez, supra note 28, at 722 (stating
that "[a]dvances in medical technology and their use partially account for the rising costs of
medicine").
30. See Sharon Reece, The Circuitous Journey to the Patients' Bill of Rights: Winners and
Losers, 65 ALB. L. REV. 17, 23 (2001) (stating that the fee-for-service model of health care was
criticized "as a significant contributor to the risein health care costs"). The fee-for-service
arrangement provides a fee to be paid to the health care provider "for each service provided either
directly by the insurance company or directly by the patient and reimbursed by the insurance
company." Id. at 22. The fee paid to the health care provider was proportionate to the service
provided. See id. at 23. The fee-for-service arrangement was an invitation for physicians or health
care providers to prescribe inordinate amounts of care, regardless of cost. See id.
31. See Allison Faber Walsh, Note, The Legal Attack on Cost Containment Mechanisms: The
Expansion of Liabilityfor Physiciansand Managed Care Organizations,31 J. MARSHALL L. REV.
207,213 n.31 (1997); see also Gonzalez, supra note 28, at 723.
32. Gonzalez, supra note 28, at 723 n.49.
33. See Walsh, supra note 31, at 213 n.31.
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decrease their exposure to medical malpractice lawsuits.' Finally, the
rising costs could be most attributable to the corporatization of health
care and the struggle for pharmacies, doctors, hospitals, pharmaceutical
manufacturers, and health insurance companies to earn profits
simultaneously.35 Despite these rising costs, other countries provide their
citizens with better health care at lower costs.36
In response to increasing costs and decreasing care, former
President William Jefferson Clinton sought to reform health care by
creating a system that would keep the cost of health care down while
providing for care for "the entire population."3 7 Clinton criticized the
health care system in the United States and saw shame in the fact "that
'infants die at rates that exceed countries blessed with far fewer
resources"' and that "insurance companies routinely deny coverage to
consumers with pre-existing conditions."38 The reform sought by Clinton
ultimately failed."
The demise of the proposed health care reform ultimately led to the
expansion of managed care plans that promised to provide health care at
a reduced cost.4 A cost-containment mechanism was needed to put the
cap on rising health care costs. 4' MCOs came to the rescue, promising to
lower health care costs by managing health care and eliminating
unnecessary medical treatment.4 1 This promise of greater care at lower
costs caught on quickly, making MCOs a popular choice among those in
search of a quality health insurance plan.4 3 By the year 1995, just months
after the failure of then President Clinton's proposed reform, seventy-

34. Seeid. at214n.31.
35. See id. at 359. In the ten year period spanning 1960 to 1970, hospital costs have risen 170
percent while doctors' fees have risen sixty percent. See EDWARD M. KENNEDY, IN CRITICAL
CONDITION: THE CRISIS IN AMERICA'S HEALTH CARE 54 (1972).
36. See ANDREWS, supra note 18, at 37 (citing a 1987 study which found that American

doctors earn 5.4 times the salary of the average worker as opposed to the United Kingdom whose
doctors earn only 2.4 times the average worker); KENNEDY, supra note 35, at 220 (stating that the
"United States pays more per capita for health care than any other industrialized nation in the world,
but it gets less health care"). For example, the life expectancy for men and women in the United
States ranks globally seventeenth and sixteenth, respectively. See ANDREWS, supra note 18.
37. See BIRENBAUM, supra note 28, at ix. ANDREWS, supra note 18, at 50.
38. ANDREws, supra note 18, at 50.
39. See BIRENBAUM, supra note 28, at ix.
40. See id.
41. See NWalsh, supra note 31, at 238.
42. See Thomas Maier, Managed Care and Doctors: The Broken Promise/HMOs and the
Critical Lists/Managed Care Promises Only the Best, but Dozens of Their Doctors Have Troubled
Pasts, NEWSDAY, Nov. 14, 1999, at A4 (reporting that managed care promised "to lower health care
costs while raising quality.").
43. See Walsh, supra note 31, at 238 n.244.
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five percent of employees in the United States who were insured were
part of a managed care organization." This was up dramatically from
fifty percent participation in managed care in the year 1993. 45
We have seen the fuel for the rise in the prevalence of managed
care plans, but not yet examined is the question of what exactly is
managed care. Managed care may be defined as
any health care arrangement in which, for a pre-set fee (i.e., the
premium), a company sells a defined package of benefits to a
purchaser, with services furnished to enrolled members through a
network of participating providers who operate under written
contractual or employment agreements, and whose selection and
authority to furnish covered benefits is controlled by the managed care
46
company.
Managed care differs from traditional health insurance in a number
of regards.47 Under traditional indemnity insurance, the insurance
company contracts to reimburse the insured for the amount spent on
health care. 48 There is no agreement between physicians/providers
("Providers") 49 and the insurance company; the patient chooses his
Provider, the Provider bills the patient, and the patient subsequently
submits the bill to the insurance company for indemnification. 0 Under a
traditional service benefit plan, Providers have contracts that dictate their
rights and duties as well as the fees that they can charge." These types of
insurance plans, similar to the one previously mentioned and contrary to
the managed care model, merely sell coverage and not care. The
capitalized plan model further sets forth a contract directly between the
Provider and managed care organization in which the physician is paid a
pre-set fee and in turn promises to provide care for all patients enrolled
in the managed care plan. 3

44. See BIRENBAUM, supra note 28, at x.
45. See id. (referring to a national survey of approximately 2000 employers).
46. RAND E. ROSENBLATr ET AL., LAW AND THE AMERICAN HEALTH CARE SYSTEM 551-52
(1997).
47. For purposes of this Note, Managed Care Organization ("MCO") will also include Health
Maintenance Organizations, Preferred Provider Organizations, and all other structures of insurers
prevalent in the marketplace today.
48. See ROSENBLATr ET AL., supra note 46, at 553.
49. When using the term Provider, this Note refers to physicians, hospitals, pharmacies,
laboratories, and other health care providers who may provide services for the insured patient.
50. See ROSENBLATT ET AL., supra note 46, at 553.
51. See id.
52. See id.
53. See id.
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Traditionally, medical care in the United States has been provided on a
"fee-for-service" basis-a physician charges for a service, billing
either the patient or the insurer. Under [the Managed Care] system, the
physician balances the financial incentive to provide more services
against the professional obligation to the patient to exercise reasonable
medical care and judgment. 4
Networks of Providers are characteristic of MCOs. 5' The network is
the term given to the group of Providers who choose to enroll with an
MCO and provide care for the organizations' enrolled patients. 6 These
Providers, who are under contract with the MCO, then provide care for
those insured by it.5 7 The Providers are also subject to the control of the
MCO in the tests and treatment they may offer. 5 Physicians are
"encouraged to see [their] patients with as little frequency as possible, to
limit testing, and to make as few referrals to specialists" as possible59
Patients are conversely told by the MCO that they are permitted to see
those physicians who participate in the plan as often as they like.6° The
physicians are told by the MCO to limit unnecessary visits by patients.'
The MCO is essentially trying to assure their enrollees that they will
receive as much quality care as necessary while requiring the Providers
to reduce costs and limit care.62 The bottom line is the bottom line of the
Insurance company's balance sheet. 63
Managed care gained its popularity by promising to lower the cost
of health care64 The system acts as a cost containment mechanism aimed
at negating the drastic rise in health care costs. 65 The key to managed54. Walker v. Group Health Servs., Inc., 37 P.3d 749, 751 n.1 (Okla. 2001) (citing Pegram v.
Herdrich, 530 U.S. 211 (2000)).
55. See ROSENBLATr Er AL., supra note 46, at 555; see also Steve Sakson, Making Healthy
Choices About an HMO: It's Smart to Comparison-Shop and Scour Benefits Books for What is
Covered andExcluded, CHI. TRIB., July 23, 1996, at 3.
56. See ROSENBLATr Er AL., supranote 46, at 555.
57. See id. at 560.
58. See BIRENBA.M, supranote 28, at 15, 20.
59. Id. at 21.
60. See id.
61. See id. at 27 (stating that "providers are watched carefully to make sure they do not
provide unnecessary care").
62. See id.
63. See KENNEDY, supranote 35, at 13 (stating that the health insurance industry in America
makes huge profits out of patient premiums while doing little to ensure quality care); see also
KENMAN L. WONG, MEDICINE AND THE MARKETPLACE: THE MORAL DIMENSIONS OF MANAGED
CARE 2 (1998) (stating that "[m]anaged care has had some success in stabilizing costs, but there are
also suspicions that its success has been achieved at the direct expense of patient health").
64. See ANDREWs, supranote 18, at 30 (stating "[mianaged care was supposed to enable the
insurance company to reduce costs"); WONG, supranote 63, at 2.
65. See Walker v. Group Health Servs., Inc., 37 P.3d 749,751 n.1 (Okla. 2001).
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care cost control is preventative medicine-that is discovering or
preventing a problem through immunizations, medications or low-cost
diagnostic tests, before the problem becomes a high-cost medical
problem.66 Examples of this include inoculations to prevent infectious
disease and prenatal examinations to prevent expensive premature births
or other gestational problems.
III. THE PREVENTATIVE MEDICINE-CURATIVE MEDICINE
NON-DISTINCTION

While MCOs promise care at a reduced cost by way of preventative
medicine, many treatments or tests are not covered. 6s MCOs have
restrictions and exclusions that at the end of this section will be
identified as preventative medicine. The truth of the matter is that the
practice of medicine, almost the entire practice of medicine, can be
classified as preventative medicine.
A number of examples will help to illustrate this proposition. Many
children suffer from otitis media, or ear infections, as many mothers
know it.69 One of the more heavily prescribed drugs for otitis media is
Zithromax (azithromycin). 70 Another popular remedy for the pain
associated with otitis media is to insert a few drops of warm olive oil
into the infected ear.7' While this may appear to be curative, it is also
preventative-the olive oil will prevent further pain and while
Zithromax may treat the underlying infection, it is also preventing
progression of the infection, possibly from spreading to an uninfected
body part, or even causing deafness. 2

66. See ANDREWS, supra note 18, at 30 (stating that part of the cost cutting campaign was
"'saturation of care at early phases of typical problems").
67. See id.
68. See id. at 31.
69. See Marilyn Chase, Drug-resistantBacteria are Bugging Little Ears, FORT WORTH STARTELEGRAM, April 18, 1999, at 13 (blaming otitis media for twenty-six million doctor visits per
year).
70. See id. (indicating Zithromax as a common treatment for otitis media).
71. See Martha Schindler, Now Ear This, VEGETARIAN TIMES, Sept. 1998, at 58 (indicating
olive oil as relief for pain associated with otitis media).
72. See id. Most pediatricians will put a child with an ear infection on antibiotics immediately
without checking to see if the infection is bacterial (only half are). See id. Antibiotics have a
tendency to build up bacteria's resistance and lead to recurrent and chronic infections. See id. The
alternative holistic remedies are more effective, readily available and cheaper than antibiotics. See
id.; see also Susan H. Thompson, Why am I Deaf?., TAMPA TRIB., Aug. 19, 2001, at 8 (indicating
that otitis media is one of the most common causes of loss of hearing in children).
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Another common ailment is the flu, where body temperatures can
reach in excess of 103 degrees Fahrenheit.73 Ibuprofen is often
prescribed to reduce the fever.74 While it may seem that the medication
was treating the fever, it was also preventing the condition from getting
worse; when a fever is not lowered, it may continue to rise, ultimately to
106 degrees, possibly leading to death. 7s
Internal bleeding may occur when an organ, such as the spleen, is
ruptured.76 Physicians will operate to repair the damaged organ.77 While
this may be deemed curative, it also prevents further bleeding, which if
left untreated, could eventually result in death.78
Hypertension is a fancy way of telling someone that they have high
blood pressure. 79 Physicians will often prescribe an ACE-inhibitor to
control the blood pressure as well as modifying diet by decreasing
sodium intake'o While this may seem to be curative, it also prevents
hypertension progressing to the point of heart attack."
These examples illustrate that when we look at medicine in a way
that examines the outcome had treatment not been initiated, it becomes
difficult to distinguish between curative and preventative medicine.
Managed care relies on the preventative medicine model to achieve
decreased costs,82 but when the distinction between preventative
medicine and curative medicine becomes difficult to establish, a new
standard is necessary. This Note now argues that the standard for
whether or not a particular treatment should be covered by a managed
care plan should be the reasonableness standard.
73. See Bernice McShane, Help Fever be a Friend,Not Foe, SUNDAY OKLAHOMAN, Jan. 29,
1995, at 3 (indicating that the flu can cause body temperature to rise to 103 degrees).
74. See Nancy H. Montville & Mary A. White, Diagnosisand PharmacologicalManagement
of Acute Otitis Media, PEDIATRIC NURSING, Sept. - Oct. 1998, at 423 (indicating Ibuprofen as an
antipyretic).
75. See Joseph B. Verrengia, Heat Deaths Are All too Common, CHATrANOOGA TIMES, Aug.
2. 2001 at D2 (indicating that death occurs at body temperatures above 106 degrees).
76. See, e.g., Fosberg Takes Extended Leave, N.Y. TIMES, Sept. 17, 2001, at 19 (discussing
how doctors had to operate on a hockey player's spleen, after it ruptured, in order to stop the
internal bleeding).
77. See id.
78. See Jules Crittenden & Dave Wedge, Man Charged ForAlleged Punch That Killed Pal,
BOSTON HERALD, Apr. 14, 2002, at 14 (noting that a man died as a result of internal bleeding after
being punched in the stomach).
79. See Morris J. Brown, Blood-Pressure-LoweringTreatment, LANCET, Mar. 3, 2001, at 715
(discussing how when treating hypertension, the goal is to reduce blood pressure).
80. See id.; see also Joseph Graedon & Teresa Graedon, The People's Pharmacy: Undoing
the Effects of Laxative Abuse, NEWSDAY, Apr. 2, 2002, at D4 (noting that a diet low in sodium
might help lower blood pressure).
81. See Brown, supra note 79, at 717.
82. See BIRENBAUM, supra note 28, at 17.
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IV. THE REASONABLENESS STANDARD
Maybe more than any other industry, managed care administrators
are forced to make decisions that may ultimately cause harm to a great
number of individuals who rely on their service. The administrator of a
managed care plan is often forced to decide between insuring an
expensive state of the art treatment with potential medical benefits or
refusing such coverage and subjecting patients to older, less expensive,
less beneficial treatments. 83 It denies these more expensive treatments on
the ground that "some treatment or service is not medically necessary."'M
The ultimate decision comes down to dollars and cents for the managed
care administrator, but sometimes on the patient level, the decision is the
difference between life and death. The MCOs may decide to reject a new
therapy on the grounds that the benefit over the existing treatment is
minimal while the excess costs are great. 8' This, however, would hardly
console the patient whose life could have been saved given the minimal
additional benefit.
In running any successful business, it is necessary to take into
account many costs and benefits.86 Thus, as a business, it is
understandable that administrators often take into account the costs and
benefits of treatments in making the ultimate decision as to whether to
insure such treatment. However, this Note argues that MCO decisions
should be judged by the reasonableness standard established over fifty
years ago.
In the year 1947, the Honorable Learned Hand authored the
landmark opinion in United States v. Carroll Towing Co.,8 in which it
was established that costs are to be considered in determining whether a
party is negligent.88 The formula in determining a party's liability for
negligent conduct as discussed in Carroll Towing Co. is that when the
probability of harm multiplied by the gravity of harm is greater than the
"burden of adequate precautions," a party's conduct is negligent.89 If the
"burden of adequate precautions" exceeds the gravity of probable harm
83. See WONG, supra note 63, at 14-15.
84. Lawrence H. Mirel, We Call it hzsurance, But That's Not Healthy, WASH. POST, Aug. 26,
2001, at B2 (arguing that "[tihe current system for paying the costs of heath care is seriously
flawed").
85. See WONG, supra note 63, at 14-15.
86. See generally Fergal Byrne, Starting on the Hard Road to a Winning Formula, FIN.
TIMES, Mar. 30, 2000, at 15 (discussing how entrepreneurs need to consider cost and benefits when
starting up a business).
87. 159 F.2d 169 (2d Cir. 1947).
88. See id. at 173.
89. See id.
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to occur, the injured party is to sustain the harm without compensation.9
The formula for negligent conduct is often cited as B < P*L ("Hand
Formula"). 9' What Carroll Towing Co. teaches us is that there will be
situations in which a party must make a decision in which harm to others
will result; these decisions are ultimately justified if the cost of
preventing the harm is greater than a function of the probability of the
harm actually occurring and the amount of harm that occurs. However,
if the harm could be prevented at a cost that is lower than probable
damage that will be sustained, the party causing the harm will be
deemed to be negligent and will be responsible for making the harmed
party whole.93
The facts in CarrollTowing Co. involved an unattended barge that
ultimately caused damage to other barges in the nearby North River. 94
The Hand Formula used in CarrollTowing Co. has not been limited to
harm caused in barge accidents. The cost-benefit analysis developed by
Learned Hand has been applied to cases involving defective oil tankers,95
defective design on cigarette cartons that fail to warn smokers of the
risks of smoking,96 banking law and negotiable instruments,97 copyright
infringement,9" contaminated blood plasma, 99 and endless other factual
scenarios.
The reason that the reasonableness standard has not yet been
applied to claims of harm caused by denied medical benefits is that such
claims are preempted by ERISA.' The "Patients' Bill of Rights" will
ultimately be passed through Congress giving patients the power to
bring tort and contract claims against MCOs.'0 ' Once MCOs are
90. See Benjamin Lange Meeker, Note, Is B Less Than PL? Economic Tort Law Analysis and
Our Public Schools: An Opportunity Foregone in Beshars v. Unified School District No. 305, 31
CREIGHTON L. REv. 1413, 1429-39 (1998) (discussing the Hand Formula); Benjamin C. Zipursky,
Legal Malpracticeand the Structure of Negligence Law, 67 FORDHAM L. REV. 649, 651-52 (1998).
91. See CarrollTowing Co., 159 F.2d at 173.
92. See id.
93. See id.
94. See id. at 170.
95. See East River S.S. Corp. v. Transamerica Delaval, Inc., 476 U.S. 858, 872, 874 (1986).
96. See Kotler v. Am. Tobacco Co., 926 F.2d 1217, 1233-35 (1st Cir. 1990).
97. See generally R.I. Hosp. Trust Nat'l Bank v. Zapata Corp., 848 F.2d 291 (1st Cir. 1988)
(applying the reasonableness standard to a bank's responsibility for forged checks after
examination).
98. See Lotus Dev. Corp. v. Paperback Software Int'l, 740 F. Supp. 37,77 (D. Mass. 1990).
99. See Vuono v. N.Y. Blood Ctr., Inc., 696 F. Supp. 743, 746 (D. Mass. 1988).
100. See CuRRAN ET AL., HEALTH CARE LAW AND ETHICS 529-31 (5th ed. 1998). For greater
detail, see discussion infra Part VI.
101. See Curing the Patients' Bill of Rights, N.Y. TIES, Sept. 4, 2001, at A22 (stating that a
"patients' rights bill is headed for a House-Senate conference committee" at which point Congress
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vulnerable to suit for negligent decisions to deny treatment, those
decisions should be judged by the reasonableness standard.
In applying this standard, a court is to use the Hand Formula to
determine whether the cost of paying for a certain procedure or
treatment is greater than the product of the magnitude of the harm that
would result from denying the treatment and the probability that such
harm would occur. Applying this formula, an MCO administrator could
deny treatment only if the cost of rendering such treatment is greater
than the harm that would be caused to the patient by failing to render
treatment. This would be considered "good harm" because the social
good exceeds the harm to the individual.'t° As an illustration, an MCO
would be justified in denying laser eye surgery to its enrollees because
the "cost of avoidance" would simply be to have its enrollees wear
glasses or contact lenses and the cost of laser eye surgery often costs
between $1500 and $2000 per eye.'0 3 On the contrary, the MCO would
be liable for a decision in which a simple glaucoma test was denied since
the cost of such a procedure is minimal and the harm that might result
includes the loss of vision."" Of course, these are simplistic examples,
and do not include a detailed examination of side effects, likelihood of
side effects, and the cost of the side effects.
V.

How ERISA BARS PLAINTIFFS FROM SUING THEIR
HEALTH INSURERS

The judicial system of the United States acts as a forum for harmed
individuals to recover damages from those who have committed the
harm.0'° When a physician or hospital causes that harm, state law
provides the plaintiff an opportunity to sue for medical malpractice. "
However, with the evolution of the health care system in America, the
will decide whether or not to adopt a law that provides for a floor of patients rights or a ceiling).
This Note assumes that the Patients' Bill of Rights will ultimately be passed into law. For greater
detail, see discussion infra Part VI.
102. See Padwa v. Hadley, 981 P.2d 1234, 1238 (N.M. Ct. App. 1999) (dismissing plaintiffs
claim for intentional infliction of emotional distress because the social good derived from
defendant's conduct far outweighed the harm).
103. See Milt Freudenheim. Just What is it that Carl Icahn Sees in Visx? Eve Laser Company
Faces New Competition, N.Y. TIMES, May 1,2001, at C1.
104. See Feature Report; Preserving Your Sight, CONSUMER REPORTS ON HEALTH, Feb. 2002.
at I (noting that if cataracts goes untreated it could cause loss of vision).
105. While this may be the case, "[t]he meagerness of the ERISA remedy in comparison to the
remedies available in a negligence suit provides HMOs with an incentive to deny care." Federal
Preemption of State Law - ERISA - Fifth Circuit Upholds State Statute Allowing HMOs To Be Sued
for Doctors' Negligence, 114 HARV. L. REV. 1406, 1409 (2001).
106. See Barracca v. St. Francis Hosp., 634 N.Y.S.2d 941,941-42 (Sup. Ct. 1995).
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physician or hospital is not always the party making the medical
decisions. '°7 This is where the legal void created by ERISA becomes
troublesome.' ERISA, originally enacted by Congress as an effort to
protect the retirement benefits of workers, was drafted so broadly as to
also encompass all benefit plans, including health insurance, provided by
employers.' 9 As such, federal law will preempt any claim that relates to
the health benefit plan, and the plaintiff seeking to recover must file their
complaint in the federal courts. " Herein lies the problem-a plaintiff
seeking to recover from a health benefit plan for harm resulting from a
denial of treatment must allege that such lack of treatment was
negligent;"' a plaintiff seeking to assert such federal tort law will
discover that no such law exists.
In order for a claim to be preempted by ERISA, the state law must
"relate to" the employee benefit plan."2 "Courts have interpreted
ERISA's preemption clause broadly" in an effort to comply with
Congress' intent to "make ERISA 'an area of exclusive federal
concern.""'" Despite the broad interpretation given to ERISA, the
"savings clause," 29 U.S.C. § 1144(b)(2)(A), provides that "[e]xcept as
provided in subparagraph (B), nothing in this subchapter shall be
construed to exempt or relieve any person from any law of any State
107. See Walsh, supra note 31, at 209.
108. See generally CURRAN, supranote 99.
109. See Larry J. Pittman, ERISA's Preemption Clause and the Health Care Industry: An
Abdication of Judicial Law-CreatingAuthority, 46 FLA. L. REv. 355, 357-58 (1994) (stating that
Congress enacted ERISA in response to "certain abuses that were occurring in employee pension
plans"). Specifically, in the early 1970s many pension plans were insufficiently funded and
employers used creative tactics to avoid compensating their long-time employees through their
pension plans. See id.at 358.
110. See id.at387.
111. See id. at 366-67.
112. See 29 U.S.C.S. § 1144(a) (1995). Specifically, the statute states "[e]xcept as provided in
subsection (b) of this section, the provisions of this [title and title IV] shall supersede any and all
State laws insofar as they may now or hereafter relate to any employee benefit plan described in
section 1003(a) of this title and not exempt under section 1003(b) of this title." Id. In order to
prevent states from disguising regulation of employee benefits as mere regulation of insurance,
Congress drafted the ERISA "deemer clause" to state as follows:
Neither an employee benefit plan.., nor any trust established under such a plan, shall be
deemed to be an insurance company or other insurer, bank, trust company, or investment
company or to be engaged in the business of insurance or banking for purposes of any
law of any State purporting to regulate insurance companies, insurance contracts, banks,
trust companies, or investment companies.
29 U.S.C. § l144(b)(2)(B) (1995). This language seems to broadly preempt any health insurer. In
order to remedy this, the "savings clause" of ERISA removes any insurance plan that is not
provided by an employer as an employee benefit. See 29 U.S.C. § 1144(b)(2)(A); see also Bill Gray
Enters. Inc., v. Gourley, 248 F.3d 206, 212 (3d Cir. 2001).
113. Gourley, 248 F.3d at 212 (citing FMC Corp. v. Holliday, 498 U.S. 52, 58 (1990)).
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which regulates insurance, banking, or securities." 4 This language
removes all non-employer provided health benefits from ERISA
preemption.5
Due to this unintended consequence of ERISA, Congress' intent to
protect employees' benefits has become frustrated because ERISA
ultimately acts as a bar to negligence suits against MCOs." 6 A suit that
has been brought in state court by a plaintiff claiming negligence against
their MCO will ultimately be removed to federal court upon the MCO's
motion.1 7 This limits the plaintiff to the equitable remedies provided for
under ERISA."' Specifically, plaintiffs will usually be limited to
reimbursement for actual plan benefits; in other words, the plaintiff may
recover the monetary value of the procedure that was denied by the
MCO, but may not be awarded monetary damages for the actual harm
that resulted from the refusal of insurance coverage for that procedure." 9
This will all soon change as the ERISA bar to state law tort claims
against MCOs will be sidestepped by the Patients' Bill of Rights.

114. 29 U.S.C. § 1144(b)(2)(A) (1995). "While ERISA broadly preempts state regulations of
employee benefit plans, it does not preempt state laws governing insurance." Gourley, 248 F.3d
at 212.
115. See Medical Mut. v. DeSoto, 245 F.3d 561, 573 (6th Cir. 2001) (stating that "[u]nder
Supreme Court precedent, a self-funded plan may not be deemed an insurance company and
therefore will be exempt from saved state laws"). The court went on to note that "[a]n insured
plan.., is deemed an insurance company and therefore is subject to the requirements of saved state
laws." Id. Thus, if a "benefit plan is an insured plan," it will not be "protected from state law by
ERISA's 'deemer clause."' Id.
116. See Pittman, supranote 109, at 361.
117. See Pryzbowski v. U.S. Healthcare, Inc., 245 F.3d. 266, 270-75 (3d Cir. 2001) (outlining
the procedure for removal to federal court and the considerations that a court must make in
determining whether the claim relates to employee benefits).
118. See Jeffrey A. Brauch, The Federal Common Law of ERISA, 21 HARV. J.L. & PUB. POL'Y
541, 547-50 (1998) (stating that Congress gave the judiciary the authority to create federal common
law in claims brought in federal court under ERISA); see also Federal Preemption of State LanERISA-Fifth Circuit Upholds State Statute Allowing HMOs to be Sued for Doctors' Negligence,
supra note 105, at 1406. For an overview of the remedies available to plaintiffs and how each
federal circuit interprets ERISA claims, see generally Brauch, supra.
119. See Richard Rouco, Available Remedies Under ERISA Section 502(a), 45 ALA. L. REV.
631, 643 (1994) (stating that damages are limited to "actual plan benefits."). For an illustration of
the limitation of remedies available under ERISA, see Mertens v. Hewitt Associates, 948 F.2d 607,
612 (9th Cir. 1991) (holding that monetary damages are not available under ERISA as a form of
equitable relief).
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VI.

THE FEDERAL AND STATE RESPONSE TO ERISA's BAR ON CLAIMS

A.

FederalResponse-The ProposedPatients' Bill of Rights

The greatest weapon that plaintiffs may have against a decision by
an MCO to deny treatment has been stuck in Congress in Conference
Committee for some time now.'20 The Patients' Bill of Rights, once

passed into law will allow plaintiffs to sue MCOs for both a lack of
quality and quantity of care.'2 ' The bill has been stuck in Conference
Committee due to the inability of the Senate and House of
Representatives to agree on the amount of damages that could be
recovered by plaintiffs.2' Ironically enough, due to recent efforts by the
judiciary to limit ERISA's "relates to" language, and thereby allow more
and more lawsuits to escape ERISA preemption, the Patients' Bill of
to benefit MCOs more than the patients it is intended to
Rights stands
2

protect."

B. JudicialResponse-Efforts to Limit the "Relate To" Language of
ERISA Allow More Claims to Be Brought in State Court
Realizing the legal void left by ERISA, and the inability of the
House of Representatives and the Senate to come to an agreement on a
definitive Patients' Bill of Rights, the federal courts have made efforts to
limit the "relates to" language of24 ERISA so as to allow more claims to
escape the pitfall of preemption.1

120. See George M. Kraw, Patient's Bill; Opportunities Abound for Insurers, FULTON
COUNTY DAILY REP., Aug. 14, 2001. Note that patients are preempted if they sue their MCOs for a
lack of quantity of care, but many state courts are now hearing claims relating to the quality of care
provided by the MCO. See In re U.S. Healthcare, Inc., 193 F.3d 151, 161 (3d Cir. 1999) (holding in
regard to complete preemption of plaintiff's quality of care claim "[n]or could we find any basis in
the legislative history [of ERISA] for concluding that quality claims, as opposed to quantity ones,
would be completely preempted").
121. See Kraw, supranote 120.
122. See id. The House of Representatives has drafted a bill that limits both compensatory and
punitive damages at 1.5 million dollars. See id. The Senates version places the recovery cap at five
million dollars. See id.
123. See id. "'IT]he plaintiff bar was finally figuring out how to get around ERISA,"' but the
new "legislation blocks the growth of state court liability theories that were opening a back door to
liability claims against insurers and HMOs." Id. Further, where in state court, there is no limit on the
amount of damages that may be recovered, the new federal law would limit those damages to some
degree. See id.
124. See, e.g., New York State Conf. of Blue Cross & Blue Shield Plans v. Travelers Ins. Co,
514 U.S. 645 (1995) (attempting to limit the "relate to" language of ERISA).
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One of the first attempts at limiting the "relate to" language of
ERISA can be seen in the case of New York State Conference of Blue
Cross & Blue Shield Plans v. Travelers Insurance Co., where the court
realized that "[i]f 'relate to' were taken to extend to the furthest stretch
of its indeterminacy, then for all practical purposes pre-emption would
never run its course."'2
The Fifth Circuit has taken the approach that a claim does not
"relate to" an ERISA plan if it applies neutrally to ERISA plans and
other types of plans.1 26 This gives a state flexibility in exercising its
police power over the quality of health care. The Texas statute at issue in
Corporate Health Insurance, Inc. v. Texas Department of Insurance
enabled patients to seek an independent review of MCO decisions as
well as holding MCOs
vicariously liable for the medical malpractice of
27
their physicians.
The Fifth Circuit gave even more flexibility to plaintiffs in their
review of Texas' efforts to provide protection to their citizens against
MCOs.128 Texas "codified an ordinary care standard for health care
treatment decisions" and allowed its citizens to bring suit if such
substandard care causes harm.. 129 A "health care treatment decision" is
defined as "a determination made when medical services are actually
provided by the health care plan and a decision which affects the quality
of the diagnosis, care, or treatment provided to the plan's insureds or
enrollees."'3 ° The Fifth Circuit interpreted the liability provisions of the
Texas statute as a claim for vicarious liability on the part of the MCO for
the negligent care of the physician as opposed to the negligence on the
part of the MCO per se.'3 ' The court went on to state that it was not
Congress' intent when drafting ERISA to supplant state regulation on
the quality of medicine.' 32 This argument is strengthened when it is taken
into consideration that Congress has never adopted a federal medical
malpractice law. The Fifth Circuit essentially treated "health care
125. Id.at 655.
126. See Corp. Health Ins., Inc. v. Texas Dep't of Ins., 215 F.3d 526, 535 (5th Cir. 2000)
(stating that -[a] law does not 'refer to' ERISA plans if it applies neutrally to ERISA plans and
other types of plans").
127. See id. at 531 (discussing the three prongs of regulation authorized by Texas Senate Bill
386). Texas also provides a statutory cause of action against MCOs. See TEX. CiV. PRAC. & REM.
CODE ANN. § 88.002 (Vernon 2002).
128. See TEX. Civ. PRAC. & REM. CODE ANN. § 88.002 (Vernon 2002) (providing a statutory
cause of action against managed care entities).
129. See Corp. Health Ins., Inc., 215 F.3d at 531.
130. TEX. CIV. PRAC. & REM. CODE ANN. § 88.001 (Vernon 2002).
131. See Corporate Health his.,
hic., 215 F.3d at 534.
132. See id. at 534-35.
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treatment decisions" as negligent when the doctor, relying on standards
set by the MCO, was unreasonable in light of ordinary care.133
The Pennsylvania Supreme Court in Pappas v. Asbel' 34 took a
similar approach. There, it was decided "ERISA does not establish a
cause of action for breach of fiduciary duty predicated upon a managed
care organization's 'mixed eligibility' decisions. ' 35 The court thereby
allowed Pappas to bring his claim against his MCO for damages
sustained from their decision to deny him a transfer to an unaffiliated
hospital that had a spinal cord trauma unit.'36
This trend, initiated by the Fifth Circuit's decision in Corporate
Health Insurance, Inc. v. Texas Department of Insurance was recently
decided by the United States Supreme Court in Rush PrudentialHMO,
Inc. v. Moran.'37 In Rush, the Supreme Court decision further limited the
"relates to" language of ERISA 3 The court held that ERISA does not
preempt plaintiffs from bringing claims against MCOs under the Illinois
HMO Act.'39 This holding further demonstrates the judicial trend to
allow more claims to be brought under state law. Along these lines, the
passage of the Patients' Bill of Rights is likely to follow. This will
require judges to adopt a standard for determining the outcomes of these
claims."' This Note now applies the proposed reasonableness standard to
an MCO's decision of whether or not to insure the prophylactic use of
Cipro in patients unexposed to anthrax.
VII. THE REASONABLENESS STANDARD APPLIED TO THE
PROPHYLACTIC USE OF CIPRO IN UNINFECTED PATIENTS

When a person has yet to be exposed to anthrax, it is unreasonable
to expect a managed care plan to insure its enrollees for prophylactic
Cipro treatment. The reason for this finding is that the overall costs of

133. See id. at535.
134. 768 A.2d 1089 (Pa. 2001).
135. Id. at 1097 (Saylor, J., dissenting) (referring to the majority's holding).
136. See id. at 1096. This is the type of case that has been historically preempted by ERISA.
See Hull v. Fallon, 188 F.3d 939, 943 (8th Cir. 1999); Danca v. Private Health Care Sys., Inc., 185
F.3d 1, 7 (1st Cir. 1999); Jass v. Prudential Health Care Plan, Inc., 88 F.3d 1482, 1495 (7th Cir.
1996); Tolton v. Am. Biodyne, Inc., 48 F.3d 937, 943 (6th Cir. 1995); Kuhl v. Lincoln Nat'l Health
Plan, 999 F.2d 298, 302 (8th Cir. 1993); Corcoran v. United Healthcare, Inc., 965 F.2d 1321, 1322
(5th Cir. 1992).
137. 122 S. Ct. 2151 (2002).
138. See generally id.
139. Seeid. at2156.
140. See Pittman, supranote 109, at 439-40.
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insuring a supply of Cipro exceeds the potential harm that could result if
a non-exposed patient did not receive such treatment.' 4'
In order to illustrate this conclusion, a survey was administered
with questions concerning the recent anthrax outbreak and prophylaxis
with Cipro. The survey read as follows:
1) Please rate your overall knowledge of
anthrax and the anthrax outbreak on a
scale of 1 - 10 with 10 being the greatest

1 2 3 4 5 6 7 8 9 10

knowledge

2) Are you concerned about catching
anthrax from an infected person
that you Yes/No
142
may come into contact with?
3) Do you know that Cipro is one of the Yes/No
treatments for anthrax?
4) If you were to receive a free 60-day
supply (standard dose of Cipro for anthrax
treatment) of Cipro from your health Yes/No
insurance
company, would you accept
143
it?

141. See infra notes 142-53 and accompanying text.
142. This question was asked as a "check" to the first question. For example, those surveys that
had '10' circled on the first question (claiming to have a lot of knowledge about anthrax) and then
had "yes" as an answer to the second question (responding that they were concerned about catching
anthrax from an infected person) were discarded as irrelevant. This is because anthrax is not
contagious and an individual with great knowledge on the topic would not be concerned about
catching anthrax. See UnderstandingAnthrax; Anthrax at a Glance, NEWSDAY, Nov. 6, 2001, at C7
[hereinafter UnderstandingAnthrax]. Thus, an answer of yes to the second question shows a lack of
knowledge on the part of the survey-taker.
143. While this question may seem to imply an obvious answer, a detailed look into the
calculation of health insurance premiums suggests a different answer. While an analysis of
insurance premiums would encompass an entire scholarly article, and is not the purpose of this
Note, a simplistic look would reveal that if massive numbers of individuals were to accept a sixty
day supply of the expensive antibiotic, insurance premiums would be adjusted upward. See Kevin
Lamb, 2001 Promises Higher Health Costs, DAYTON DAILY NEWS, Dec. 24, 2000, at IA
(comparing the rise in the use of health care services to the increase in health insurance premiums).
The results for this question show that human nature tends to respond positively to the word "free"
without consideration of the consequences, and whether something is truly free of charge.
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5) If your insurance company did not
cover Cipro, would you pay $420 for a
two month supply if it was not medically Yes/No
necessary (meaning that you were
currently in good health)?'44
6) If your insurance company did not
cover Cipro, would you pay a reduced rate
of $120 for a two month supply if it was Yes/No
not medically necessary (again meaning
that you were currently in good health)?' 45
7) If you did receive a 60-day supply of Take it to prevent infection
Cipro, what would you do with it?
or
Hold onto it "just in case"
The survey returned 186 responses 4 6 from pharmacy patients,
pharmacy technicians, nurses, physicians, hospital patients, lab
technicians and elementary school teachers. The following are the results
of the compiled data, which tend to support the argument that it would
be unreasonable to expect MCOs to insure Cipro for prophylactic
treatment when the patient is yet to be exposed to anthrax. Following the
results of the survey will be a cost-benefit analysis as is required by the
CarrollTowing decision.
The completed surveys were divided into three groups. Those who
responded between one and three on the first question were regarded as
individuals with little or no knowledge of the anthrax breakout and the
disease in general. Those answering between four and seven on the first
question were regarded as individuals with average knowledge of the
anthrax breakout and the disease in general. Those answering between
eight and ten on the first question, and responding "no" to the second
question, were regarded as individuals with superior knowledge of the
anthrax breakout and the disease in general. Those answering between
eight to ten on the first question, and "yes" to the second question, were
144. The cost of Cipro is approximately three dollars and fifty cents per tablet. See Rita Rubin,
Urinaty Infection Treatment Often Isn't First-Line Choice, USA TODAY, Jan. 14, 2002, at D7
(calculating the 10 day cost of Cipro therapy at $70.98). A sixty day supply of the drug would
therefore cost a patient approximately $420.
145. The calculation of approximately one dollar per tablet is based upon the theoretical price
that the U.S. government was negotiating with both Bayer Pharmaceuticals and generic drug
manufacturers. See Denise Gellene, Anthrax Cases Reshape Drug Price Debate, L.A. TIMES, Nov.
9, 2001, at Cl (stating that the United States is negotiating with Bayer Pharmaceuticals to purchase
Cipro at ninety-five cents per tablet).
146. This survey is on file with the Author.
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placed in the group regarded with little or no knowledge of the anthrax
breakout and the disease in general." 7
Individuals with
superior knowledge
27.4% (51/186)

Individuals with
average knowledge
56.4% (105/186)

Individuals with
inferior knowledge
16.1% (30/105)

The following is a breakdown of the responses given by the
individuals placed into the superior knowledge category:
Are you concerned
about catching
anthrax from an
infected person that
you may come into
contact with?
Do you know that
Cipro is one of the
treatments for
anthrax?
If you were to receive
a free 60-day supply
(standard dose of
Cipro for anthrax
treatment) of Cipro
from your health
insurance company, 14
would you accept it?

Yes 0% (0/5 1)

No 100% (51/51)

Yes 100% (51151)

No 0% (0/51)

Yes 82% (42/5 1)

No 18% (9/51)

147. Quite surprisingly, twenty-four, or 12.9% of all respondents fell into this category. I say
surprisingly because of the extensive publicity that has been given to the anthrax breakout, and the
repetitive assurance by President George W. Bush that anthrax is not contagious. See Michael
Kranish, Fighting TerrorNationalConcerns, BOSTON GLOBE, Nov. 4,2001, at Al.
148. This result is quite surprising. I estimated that nearly every person would respond "yes" to
this question simply because of the fact that the medication was supposed to be "free." This may
suggest that there are individuals who would not take advantage of insurance coverage when not
necessary.
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If your insurance
company did not
cover Cipro, would
you pay $420 for a
two month supply if it
was not medically
necessaty (meaning
that you were
currently in good
health)?
If your insurance
company did not
cover Cipro, would
you pay a reduced rate
of $120 for a two
month supply if it was
not medically
necessary (again
meaning that you
were currently in good
health)?
If you did receive a
60-day supply of
Cipro, what would
you do with it?

Yes 3.9% (2/51)1 9

No 96.1% (49/5 1)

Yes 33.3% (17/51)50

No 66.7% (34/51)

Take it to prevent
infection
0% (0/51)

Hold onto it "just in
case"
100% (51/51)

I

I

_I

In light of the results acquired from these individuals, this Note
poses the following question: Is it reasonable to ask an MCO, whose
goal is to reduce the rising cost of health care by cutting down on
unnecessary treatment, to insure a treatment that the beneficiary does not
intend to utilize, but merely intends to hold onto it "just in case?" It is
disturbing that an individual would rely on their MCO to insure an

149. These two individuals were both of the group who would accept the free supply from their
insurance company.
150. Of these individuals, six were of the group who would refuse the free supply from their
insurance company. This was quite surprising in that these individuals would refuse a free supply
from their insurance company but were also not willing to pay full price. The only explanation is
that these individuals did not want to defraud their MCOs, and either money was an issue or they
did not feel that there was enough of a danger to justify spending $420 for a precautionary
medication.

Published by Scholarly Commons at Hofstra Law, 2002

23

Hofstra Law Review, Vol. 30, Iss. 4 [2002], Art. 6
HOFSTRA LAW REVIEW

[Vol. 30:1329

unnecessary treatment that the beneficiary does not feel is important
enough to their health to pay for by themselves. 5
The following is a breakdown of the responses given by the
individuals placed into the average knowledge category:
Are you concerned
about catching
anthrax from an
infected person that
you may come into
contact with?
Do you know that
Cipro is one of the
treatments for
anthrax?
If you were to receive
a free 60-day supply
(standard dose of
Cipro for anthrax
treatment) of Cipro
from your health
insurance company,
would you accept it?
If your insurance
company did not
cover Cipro, would
you pay $420 for a
two month supply if it
was not medically
necessaty (meaning
that you were
currently in good
health)?

151.

Yes 21.9% (23/105)

No 79.1% (82/105)

Yes 100% (105/105)

No 0% (0/105)

Yes 69.5% (73/105)

No 30.5% (32/105)

Yes 21.9% (23/105)

No 78.1% (82/105)

This, of course, assumes that the respondent was able to afford the Cipro treatment.
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If your insurance
company did not
cover Cipro, would
you pay a reduced rate
of $120 for a two
month supply if it was
not medically
necessary (again
meaning that you
were currently in good
health)?
If you did receive a
60-day supply of
Cipro, what would
you do with it?

I

Yes 46.7% (44/105)152

No 53.3% (61/105)

Take it to prevent
infection
10.4% (11/105) 53

Hold onto it "just in
case"
89.6% (94/105)"4

_II

The responses of the individuals placed into the group with little
or no knowledge broke down as follows:
Are you concerned
about catching
anthrax from an
infected person that
you may come into
contact with?
Do you know that
Cipro is one of the
treatments for

Yes 93.3% (28/30)

No 6.7% (2/30)

Yes 100% (30/30)

No 0% (0/30)

anthrax?

152. The percentage of respondents willing to pay for the antibiotic, whether it be full price or
the reduced price, increased with the decreased knowledge (33.3% for the group with superior
knowledge vs. 46.7% for the group with moderate knowledge). This implies that those with greater
knowledge understand that Cipro will be made available by the government and that stockpiling the
drug is not necessary.
153. The implications of this answer will be discussed in the cost-benefit analysis as well as in
the discussion of what the physician and pharmacist can do to carry out the goals of the managed
care company. Briefly, this answer shows that these individuals lack the proper understanding of the
medication and the costs of taking the medication without being exposed to anthrax.
154. Once again, the great majority of individuals who would accept a supply of Cipro from
their MCOs do not believe that the medication is necessary and would simply hold it "just in case."
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If you were to receive
a free 60-day supply
(standard dose of
Cipro for anthrax
treatment) of Cipro
from your health
insurance company,
would you accept it?
If your insurance
company did not
cover Cipro, would
you pay $420 for a
two month supply if it
was not medically
necessaty (meaning
that you were
currently in good

[Vol. 30:1329

Yes 100% (30/30)

No 0% (0/30)

Yes 16.7% (5/30)

No 83.3% (25/30)

Yes 53.3% (16/30)

No 46.7% (14/30)

health)?

If your insurance
company did not
cover Cipro, would
you pay a reduced rate
of $120 for a two
month supply if it was
not medically
necessary (again
meaning that you
were currently in good
health)?

If you did receive a
60-day supply of
Cipro, what would
you do with it?

Take it to prevent
infection
36.7% (11/30)
I
_I

Hold onto it "just in
case"
63.3% (19/30)
_I

The results of the survey illustrate two important points to be
considered in answering the question of whether it is reasonable to
expect an MCO to provide insurance coverage for prophylactic Cipro
therapy when the insured is yet to be exposed to anthrax. The first point
is that it would be unreasonable to expect the MCO, whose goal is to
reduce the cost of health care, to insure a treatment which the patient
does not intend to use and does not necessarily feel is necessary to insure
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good health.'55 Secondly, those individuals who answered that they
would take Cipro in good health to prevent infection show a complete
lack of knowledge; the cost of informing these individuals about anthrax
infection is far less than the cost of paying for a two month course of
Cipro, and is thus the reasonable alternative.'56
A cost-benefit analysis of the prophylactic administration of Cipro
for persons not exposed to anthrax reaches a similar conclusion. This
Note first examines the benefits of taking Cipro for the prophylaxis of
anthrax infection when the individual has not yet been exposed.
Only a few benefits are conceivable to this use of Cipro.'5 7 Nearly
all of the respondents to the survey, whether they received the Cipro for
free or paid out of pocket, answered that they would hold onto it just in
case. This suggests that the mere possession of the antibiotic would give
them peace of mind. While this may not be easily quantified, any benefit
obtained through peace of mind is minimal. The responses to the survey
also suggest that people may fear supplies of the antibiotic may become
scarce. Government officials have repeatedly assured the public that this
will not happen and to their word, it has not happened.'5 8
Upon an examination of the costs of allowing those not yet infected
to obtain Cipro from their Managed Care plans, it becomes obvious that
these costs far outweigh the benefits, justifying the refusal of benefits by
the MCO for such use of the medication.
The first cost is the potential for the mutation of Anthrax bacteria
into a resistant strain. 9 Further, the "more people who don't have
155. The reason I come to this conclusion is that assuming the respondent could afford the
medication, the reasonable person would pay at least a reduced price for a medical treatment if they
felt it was necessary. The fact that 61% of respondents would not pay any price for the medication
indicates that they do not feel that it is medically necessary.
156. See, e.g., Frequently Asked Questions About Anthrax, supra note 10 (providing
information about anthrax to the public free of charge).
157. Contrast this to the great benefits of using Cipro for those who have known exposure to
Anthrax, or have been suspected to have been exposed to Anthrax bacteria. For these individuals,
the two-month treatment, costing their Managed Care organizations approximately $480 is far
outweighed by the benefits of treatment, since given early enough, it will prevent the patient from
developing Anthrax infection. See Stolberg, supra note 13 (noting that Cipro has become a
"household name" in the treatment of anthrax).
158. See Leslie Wayne & Melody Peterson, A Muscular Lobby Rolls Up Its Sleeves: Dng
Makers Gain Remarkable Access in Washington, N.Y. TIwEs, Nov. 4, 2001, sec. 3, at 1 (reporting
that the United States government would do whatever it takes to insure an adequate supply of Cipro
and that Bayer Pharmaceuticals has lowered the price on the drug to comply with United States
demands).
159. See Andy Dworkin, For Bacteriain a Cipro World, Resistance is Not Futile, OREGONIAN,
Nov. 28, 2001, at Cll; Sharon Lerner, Risky Chickens: Bayer Refuses to Withdraw Animal
Antibiotic that Causes Drug Resistance in Humans, VILLAGE VOICE, Dec. 4, 2001, at 45 (reporting
that "[b]ecause the vast majority of the roughly 30,000 people who took Cipro in the anthrax scare
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bacterial infections take antibiotics, the less effective the drugs are when
treating real problems, including [tuberculosis], pneumonia, and bad
colds." '6° It is estimated that thousands of U.S. residents treated
themselves with Cipro out of fear without reporting the use to the
CDC. 16 ' This increases the chances that these individuals would build a
resistance to the drug. 62 The costs and consequences of this are that the
usefulness of Cipro decreases and for those "infected by newly resistant
germs, it means they will feel worse, for a longer time, and will pay
more to get well.', 63 This negative effect is not limited to Cipro-the
entire family of powerful quinolones becomes less effective. 64 "[D]rugresistant bacteria are pushing medical costs higher while making people
sicker and cures longer and more painful."' 6 This is in direct contrast to
the ultimate end that Managed Care strives to achieve. The quantified
increase in the cost of health care in the United States due to drug
resistance is about thirty billion dollars per year.' 66 Ultimately, only
powerful intravenous antibiotics will be able to combat these germs,
meaning a trip to the local hospital.' 67 These costs alone outweigh the
potential benefits of Cipro for prophylactic purposes in non-exposed
patients, but there are other costs.
Another cost of Cipro is its actual monetary cost-which as already
stated is approximately $420 for a two-month supply.' 68 Please note that
this is an approximate retail cost, which is closer to what MCO would be
paying, as opposed to the actual cost.
As an antibiotic, Cipro contains dangers as well as side effects.' 69
The first danger is the use of Cipro by children. Since Cipro has an
affinity to bone and joints, the drug often deposits itself within the

were treating fear rather than exposure, the effectiveness of the best-selling drug was undermined
even as its sales were skyrocketing").
160. Lerer, supra note 159.
161. See Dworkin, supra note 159.
162. See id.
163. Id.
164. See id.
165. Id.
166. See id.
167. See id. One of the most frequently encountered and dangerous resistant germs are those
resistant to penicillin type antibiotics. See id. The reason for its frequency is because of fifty years
of widespread penicillin use. See id. Cipro is often used as a second line of attack, and with the
prophylactic use of Cipro for anthrax prevention, that may soon be lost as well. See id.
168. See supra note 142 and accompanying text.
169. See Dworkin, supra note 159; Reed Fujii, Demand for Cipro Not High in S.J.,
PharmacistsSay, RECORD (Cal.), Oct. 19, 2001, at F1 (explaining that Cipro can cause a number of
side effects).
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bone. 70 In children less than eighteen years of age, Cipro can "produce
erosions of cartilage of weight-bearing joints and other signs of
arthropathy..'.' Further dangers include dangerous interactions with
other pharmaceuticals. The most serious of these is the combination of
Cipro with theophylline, which can lead to cardiac arrest, seizure,
respiratory failure and death. 72 Further, antibiotics often produce
unpleasant side effects. While over one hundred side effects are listed
for Cipro, the most common (or in some cases most severe since cost is
determined by probability times degree of harm) are: nausea (5.2%),
diarrhea (2.3%), abdominal pain/discomfort (1.7%), headache (1.2%),
cardiopulmonary arrest (<1%), and renal failure (<1%).173 In order to do
a complete cost-benefit analysis, it would be necessary to multiply the
probability of occurrence times the degree of harm to establish costs."
Since pain and discomfort are subjective, quantifying them would be
nearly impossible. For example, 2.3 out of every one hundred
individuals develop diarrhea; the cost of diarrhea could be determined by
measuring the amount of discomfort and the cost of treatment-for
example, a few doses of Imodium. Such a detailed cost-benefit analysis
is not necessary for purposes of concluding that Cipro prophylaxis in
individuals not exposed to anthrax bacteria is not necessary. All that is
necessary to ask is whether the minimal value of peace of mind and the
risk of Cipro supplies running short exceed the value of developing
dangerous resistant bacteria, the cost of potential bone malformation in
children, and the discomfort of the side effects of Cipro plus $420 in
actual cost.
If you have not yet determined that the cost of Cipro use in
unexposed individuals far outweighs the benefits of such use, consider
that Anthrax infection can be prevented by administering Cipro up to
seven to ten days after exposure. 7' Further corroborating the conclusion
of this Note is the fact that there are adequate supplies of Cipro so as to

170. See id.; Fujii, supra note 169 (reporting that Cipro "has been linked to a degenerative joint
disease that could attack those whose bones and sinews are still growing").
at
12,
available
at
Label
Tablet/Suspension
of
Cipro
171. Reprint
www.fda.gov/ohrmsldocketslac/OObackgrd/3662blaO4.pdf (dated Aug. 29,2000).
172. See id. at 14. Theophylline is a common medication used in the treatment of asthma. See
at
available
Asthma,
Center:
Information
Drug
http://wvv.lungusa.org/asthmalascastnedgr.html#preventive (last visited Jan. 4, 2002).
173. See id.
174. In a litigation setting, it is likely that expert witnesses would be required to present this
data.
175. See Ivan Oransky, Antibiotic Overuse Can Silence Medicine's Big Guns, USA TODAY,
Nov. 15, 2001, at 15A (noting that originally Cipro was only to be taken for seven to ten days).
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make stockpiling the drug unnecessary.7 7 As this Note establishes
MCOs are not obligated to insure Cipro prophylaxis since such use
would be unreasonable.' 7 This Note now discusses the health care
providers' role in decreasing the cost of health care.
VIII.

THE PROVIDERS' ROLE

In the Managed Care setting, the doctor agrees to provide care to
the patient, but at the same time agrees with the MCO that he will only
order such treatment as is medically necessary. 178 As Cipro is an
important antibiotic for the treatment of many bacterial infections,' 9 it
would be unreasonable to ask MCOs to deny coverage for all Cipro
regimens. The reasonable alternative would be to rely on the physician
to refuse to prescribe Cipro outside the ordinary course of treatment. The
physician's role upon being asked for a Cipro prescription would be to
educate the patient concerning the dangers of arbitrarily taking Cipro as
well as informing the patient about Anthrax infection itself. The data
compiled in the survey suggests that the less information an individual
has regarding anthrax infection, the greater he or she fears contracting
the disease from an infected person. With greater information, these
individuals may understand that anthrax is not contagious, and
stockpiling Cipro or, even worse, arbitrarily taking the drug for
prophylactic purposes is simply not necessary when there has been no
anthrax exposure. The cost of this education session might be to take a
few minutes of the physician's time each day (when patients ask for
Cipro prescriptions) to educate patients. The benefit however, of
avoiding unnecessary Cipro prophylaxis would make up for this cost. If
time is an issue for the physician, the MCO could develop informational
pamphlets to be administered to patients who ask for Cipro
prescriptions.
The pharmacist, another provider in the Managed Care structure,
can also play a role in preventing the widespread prophylactic use of
Cipro. As the last line of defense between the patient and the medication,
the pharmacist can refuse to either fill a two-month prescription for
Cipro or actually fill the prescription but refuse to bill the MCO, thereby
requiring the patient to pay cash. It is possible that MCOs will bill

176.
177.
178.
179.

See Fujii, supra note 169.
See id.
See Mirel, supra note 84.
See Stolberg, supra note 13.
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pharmacies back for suspicious Cipro prescriptions."" This gives
pharmacists a justification for refusing to bill insurance carriers for such
prescriptions. An alternative to this would be for insurance
administrators to electronically refuse such Cipro treatments by
automatically refusing any Cipro prescription with a regimen of thirty or
sixty days.'
Ultimately, it becomes apparent that there is not much that the
MCO can do without the help of other Providers. It is up to physicians
and pharmacists to provide information to educate the patient. Further,
the Provider must work to keep health care costs down by refusing to
prescribe or administer any prescriptions for Cipro that are not medically
necessary.
IX. CONCLUSION
Recent events have left the public unsettled and wondering from
where the next harm will come. Recent fears center on unprecedented
bioterrorism involving Anthrax. 82 Individuals have looked to their health
care professionals for Cipro, a treatment for Anthrax, in order to calm
their fears.'83 For those health care professionals, it is unreasonable for
them to accommodate those patients. Further, the act of prescribing
Cipro for patients not exposed to Anthrax bacteria violates the
agreement the physician has with the MCO which obliges the physician
to only render such care as is medically necessary. The reason such
treatment is unnecessary is that the harm caused to society and the
individual by such treatment far outweighs any benefits that it may have.
This reasonableness standard has been applied to many different
areas in the past beginning with the case of Carroll Towing in which
Learned Hand developed the formula for reasonableness as B < P * L.
This standard has yet to be applied in cases where an MCO decision not
to insure a specific treatment is at issue. The reason for this legal void is
ERISA, which preempts such claims from being brought in state court.
When brought in federal court, plaintiffs find themselves without any
tort law precedent. Congress, realizing that this legal void gives patients
no bargaining power with their MCO, and often leaves patients with no
180. Interview with Carol Martin, Supervisor, National Prescription Administrators, in East
Hanover, N.J. (Dec. 12, 2001).
181. AdvancePCS has taken this approach by limiting Cipro prescriptions to twenty-eight pills
or a fourteen day supply. Interview with Thomas Reidlinger, Supervisor, AdvancePCS, in
Richardson, Tex. (Dec. 3, 2001).
182. See supra notes 8-11 and accompanying text.
183. See supra notes 12-13 and accompanying text.
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recourse when an MCO denies treatment, has begun to consider a
Patients' Bill of Rights. When adopted, the Patients' Bill of Rights will
give patients the ability to bring tort and contract claims against their
MCO. Some state courts have already begun to sidestep ERISA by
allowing some borderline claims to be heard. When hearing such claims,
the courts construing state statutes have applied a reasonableness
standard. This is the standard that should be applied to all "health care
treatment decisions." In other words, an MCO would be justified in
denying any treatment to a patient when the cost of such treatment is
outweighed by the potential harms as measured by the Hand Formula. If
the MCO denies treatment when the benefits of the treatment outweigh
the cost, they will be liable for the resulting harm that arose from the
decision to deny treatment. The Hand Formula for measuring
reasonableness has been successfully applied to many industries in the
past, and there is no reason to believe that it should not be applied to
MCO decisions in the future.
Daniel L. Freidlin*

* This Note is the product of many life-altering decisions, not the least of which was turning
my back on the well-respected profession of Pharmacy. For their endless support throughout this
transitional period in my life, their guidance, and encouragement, this Note is dedicated to my
parents, Boris and Mila Freidlin, without whom I would be unable to achieve success throughout
my academic and professional endeavors. I would like to thank Dr. Joel Weintraub, J.D., who
planted the seed which gave rise to this Note, and whose stream of insight helped it to grow into this
finished product. My deepest gratitude to the Board of Editors and Staff of the Hofstra Law Review
for their ongoing dedication to excellence, and their tireless efforts in preparing this Note for
publication. One day Health Care in America may be more about health and less about dollars; until
that day, I hope this Note has provided some insight into how the law can make Health Care a more
efficient system.
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